EBIT: Income before interest and taxes.
Tango Therapeutics, Inc. (TNGX) had EBIT of $-78.12M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-68.39M |
|
-- |
|
-- |
|
$78.12M |
|
$-78.12M |
|
$9.72M |
|
$-68.39M |
|
$-68.39M |
|
$-68.39M |
|
$-68.39M |
|
$-68.39M |
|
$-68.39M |
|
|
EBIT |
$-78.12M |
$-79.90M |
|
173.93M |
|
173.93M |
|
$-0.39 |
|
$-0.39 |
|
| Balance Sheet Financials | |
$992.66M |
|
$5.75M |
|
$40.80M |
|
$1.03B |
|
$25.16M |
|
-- |
|
$28.12M |
|
$53.29M |
|
$980.17M |
|
$980.17M |
|
$980.17M |
|
169.21M |
|
| Cash Flow Statement Financials | |
$-120.37M |
|
$-660.32M |
|
$754.82M |
|
$114.85M |
|
$88.97M |
|
$-25.87M |
|
$52.59M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
39.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-120.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.98% |
|
-6.98% |
|
-6.62% |
|
-6.98% |
|
$5.79 |
|
$-0.69 |
|
$-0.69 |
|